ROS1 and neoplasm: No differences in NAE frequency were identified between patients reported as Asian versus non-Asian, or according to tumor mutation status, ALK-positive versus ROS1-positive NSCLCs, or by the presence versus absence of CNS metastases (Supplementary Figures S3–S5).